Science 37

02/26/2026

𝗦𝗖𝗢𝗣𝗘 𝟮𝟬𝟮𝟲 𝗶𝗻 𝗢𝗿𝗹𝗮𝗻𝗱𝗼 🌴 — 𝗼𝘂𝗿 𝗯𝗲𝘀𝘁 𝘆𝗲𝘁.

From nonstop booth traffic to meaningful conversations about the future of clinical trials, the energy this year was unmatched. We loved seeing so much interest in how Science 37 𝗼𝗽𝗲𝗿𝗮𝘁𝗲𝘀 𝗮𝘀 𝗮 𝗰𝗹𝗶𝗻𝗶𝗰𝗮𝗹 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 𝘀𝗶𝘁𝗲—𝗯𝗿𝗶𝗻𝗴𝗶𝗻𝗴 𝘁𝗿𝗶𝗮𝗹𝘀 𝗱𝗶𝗿𝗲𝗰𝘁𝗹𝘆 𝘁𝗼 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀.

🏠 𝗔𝘁 𝗼𝘂𝗿 𝗯𝗼𝗼𝘁𝗵
Our “living room” was buzzing all week as attendees stepped in for our first-ever live, at-home demos—getting a firsthand look at how our team delivers FDA-compliant, direct-to-patient trials.

🐢 𝗧𝘂𝗿𝘁𝗹𝗲𝘀 𝗳𝗼𝗿 𝗴𝗼𝗼𝗱
Together, we supported children’s hospitals advancing clinical research—thank you to everyone who joined us in giving back.

🏆 𝗔𝘄𝗮𝗿𝗱𝘀 𝗿𝗲𝗰𝗼𝗴𝗻𝗶𝘁𝗶𝗼𝗻
We’re proud to have been named a finalist for both the 𝗦𝗶𝘁𝗲 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻 𝗔𝘄𝗮𝗿𝗱 and the 𝗣𝗮𝗿𝘁𝗶𝗰𝗶𝗽𝗮𝗻𝘁 𝗘𝗻𝗴𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗔𝘄𝗮𝗿𝗱.

🎤 𝗣𝗮𝗻𝗲𝗹 𝗵𝗶𝗴𝗵𝗹𝗶𝗴𝗵𝘁𝘀
Huge thanks to Debra Weinstein, Arthur Van Leerberghe, Maria I. Florez, John Reites, and Michelle Giovannucci, RPh, for sharing insights on embedding flexibility early in trial design.

💚 𝗧𝗵𝗮𝗻𝗸 𝘆𝗼𝘂
To everyone who stopped by, joined a demo, or sparked a conversation...thank you for making SCOPE 2026 one to remember.

Missed us onsite or want to keep the conversation going? We’d love to connect: https://lnkd.in/gpxk9gN8

SCOPE 365

02/24/2026

For individuals living with Lennox-Gastaut Syndrome (LGS), growing up brings new challenges — especially when it comes to transitioning from pediatric to adult care. Planning ahead and understanding what to expect can make this shift smoother for patients and caregivers alike.

💜 Learn how to navigate the transition to adult care when LGS grows up and explore resources designed to support families through every stage.
👉 https://studies.science37.com/when-lgs-grows-up-navigating-the-transition-to-adult-care/?&

When a child is diagnosed with Lennox-Gastaut Syndrome (LGS), the focus is almost exclusively on the "now." Parents are consumed by managing daily seizures, navigating developmental delays, and fighting for the best pediatric care. But children with LGS do grow up. Thanks to advances in medical care...

02/20/2026

Back for year two at 2026 🩺

We’re proud to continue supporting nurses who are exploring clinical research as an impactful and patient-centered career path.

Excited to be partnering again with the Modern Nurse Fest team!

02/18/2026

🐢 𝗦𝗵𝗲𝗹𝗹𝘆’𝘀 𝗦𝗖𝗢𝗣𝗘 𝗠𝗶𝘀𝘀𝗶𝗼𝗻 𝗖𝗼𝗺𝗽𝗹𝗲𝘁𝗲!
At SCOPE, our 𝗧𝘂𝗿𝘁𝗹𝗲𝘀 𝗳𝗼𝗿 𝗚𝗼𝗼𝗱 tradition continued — and thanks to everyone who stopped by our booth, Shelly has officially found her new home at Orlando Health Arnold Palmer Hospital for Children, along with a donation made on behalf of Science 37.

Shelly will be there to bring smiles, comfort, and a little extra joy to children and families. 💚

Thank you to everyone who joined us at SCOPE and helped turn those connections into something that gives back beyond the conference walls.

02/13/2026

At Science 37, we’re building a team focused on solving one of clinical research’s biggest challenges: making trials more accessible so patients can participate, regardless of their location within the U.S.

We’re currently hiring for several exciting roles, including:

• Survey Designer Analyst, Patient Recruitment
• Associate Director, Strategic Solutions (West Coast)
• Travel Per Diem Mobile Research Nurse (Multiple Locations)

If you’re passionate about advancing clinical research and improving the patient experience, we’d love to connect.

👉 Explore our open roles and apply here: https://lnkd.in/eBMPeYta

02/13/2026

If you are a parent or caregiver navigating a recent Dravet Syndrome diagnosis, you likely feel overwhelmed by medical terminology and the sudden shift in your family’s life. While the journey is difficult, advancements in rare disease research and participating in rare disease trials are opening new doors for families who need them most.

Learn more from our blog:
https://studies.science37.com/navigating-dravet-syndrome-a-guide-for-caregivers-on-rare-epilepsy/

02/10/2026

Obesity is not a failure of character; it is a complex, chronic disease. It is influenced by a web of factors including genetic factors in obesity, environmental triggers, and powerful biological mechanisms that often fight against weight loss. By understanding the science behind the condition, we can reduce the stigma, embrace patient-centric care, and explore new paths to long-term health.

Learn more:
https://studies.science37.com/beyond-willpower-the-science-of-obesity-new-paths-to-management/

02/06/2026

Join Us at !

Stop by the Science 37 booth to learn how adding our site to your study can help you reach more patients—𝗮𝗻𝘆𝘄𝗵𝗲𝗿𝗲 𝗶𝗻 𝘁𝗵𝗲 𝗨.𝗦.

Our 𝗗𝗶𝗿𝗲𝗰𝘁-𝘁𝗼-𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗦𝗶𝘁𝗲 brings the trial to the patient, removing barriers of travel and access without compromising data quality.

Connect with Scott Arceri and Ben Herron at 𝗯𝗼𝗼𝘁𝗵 #𝟭𝟭𝗯, who will be onsite, ready to answer your questions and discuss how our team can support your new or ongoing study. 🤝

02/04/2026

We are thrilled to welcome Kelly McKee to the Science 37 leadership team!
As our new 𝗩𝗶𝗰𝗲 𝗣𝗿𝗲𝘀𝗶𝗱𝗲𝗻𝘁 𝗼𝗳 𝗦𝘁𝗿𝗮𝘁𝗲𝗴𝘆 & 𝗧𝗿𝗮𝗻𝘀𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻, Kelly will lead the design of our future-state patient experience—driving growth through modernized trial ex*****on, advancing innovation, and strengthening cross-organizational collaboration to support long-term growth.

https://www.science37.com/science-37-appoints-kelly-johnston-mckee-as-vp-of-strategy-transformation/

02/02/2026

𝗦𝗵𝗲𝗹𝗹𝘆 𝗶𝘀 𝗯𝗮𝗰𝗸 🐢 𝗮𝘁 𝗦𝗖𝗢𝗣𝗘!

Stop by Booth #301 to support local children’s hospitals advancing clinical research.

𝗛𝗼𝘄 𝗶𝘁 𝘄𝗼𝗿𝗸𝘀:
• Visit Booth #301
• Choose a charity — we’ll donate on your behalf
• Take home a mini Shelly the Sea Turtle

Your support helps make a meaningful impact — both inside and outside clinical trials.

Plus: Watch our live at-home demos in action to see how we’re bringing trials directly to patients. 🏠

https://lnkd.in/eZm-jXKN

01/28/2026

CASE STUDY: Primary Biliary Cholangitis (PBC)
Enrolling 47% of Total U.S. Participants for a Phase 3 Hepatology Trial
Science 37 was the top enrolling site, contributing 47% of total U.S. study participants. Despite joining the trial 6 months later, enrollment was 11x faster compared to the other 141 participating traditional brick-and-mortar sites. Science 37 also achieved an 82% retention rate in patients transferred from traditional sites who were at risk of dropping out.

View the Case Study :https://www.science37.com/wp-content/uploads/2025/07/Science_37_Case_Studies_PBC-1.pdf

01/26/2026

Clinical trials are evolving, and regulators are taking notice. As research continues to move beyond traditional sites, decentralized trial elements are becoming a key part of making studies more accessible, efficient, and patient-centric.

🔬 Learn why the FDA’s recognition of decentralized trial elements matters and what it means for the future of clinical research in this latest blog from Science 37:
👉 Read the full article here:

In its Final Guidance on Decentralized Clinical Trials, the FDA provides recommendations for trial sponsors […]